Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108341 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
A Phase 2 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01108341 is a Phase 2 study that has completed, run by Cephalon. The registered enrollment target is 50 participants.
The verdict
NCT01108341, a Phase 2 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the efficacy, as measured by overall response (complete response + partial response) of bendamustine in combination with ofatumumab in previously untreated patients with indolent B-Cell Non-Hodgkin's Lymphoma (NHL).
Interventions
- DRUG Ofatumumab
- DRUG Bendamustine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01108341
The ClinicalTrials.gov registry entry for NCT01108341 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ofatumumab is the first listed.
NCT01108341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01108341 about?
NCT01108341 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)". The primary objective of the study is to determine the efficacy, as measured by overall response (complete response + partial response) of bendamustine in combination with ofatumumab in previously untreated patients with indolent B-Cell Non-Hodgkin's Lymphoma (NHL).
What is the current status of trial NCT01108341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01108341?
The interventions under investigation include: Ofatumumab (DRUG), Bendamustine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01108341?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.